In this article, we will discuss the 10 Best Performing NASDAQ Stocks According to Wall Street Analysts.
On April 28, Tom Lee of Fundstrat joined CNBC’s ‘Power Lunch’ to discuss the outlook for equity markets. Lee explained that the stock market is currently navigating three primary risks identified at the start of the year: the potential escalation of the war in Iran, concerns regarding private credit, and the transition to a new Fed chair. Lee asserted that the market has largely passed the test concerning the Iran conflict, as the economy has shown remarkable strength, and earnings estimates have actually risen. He also notes that private credit underwriting is performing better than expected, as evidenced by the rebound in the IGB software ETF. Since many private credit loans were tied to software, the recovery of the ETF from a low of 72 back to 85 suggests that this is no longer a structural problem. Consequently, Lee believes that the upside case for stocks is strengthening, making an S&P 500 level above 7,700 highly probable.
Several planks support this bullish outlook, including higher earnings estimates and the productivity gains delivered by AI. Lee referenced the positive case for AI, which includes business growth and company formation. Furthermore, he anticipates that the risk premium will drop later this year if the Middle East situation is resolved, as it would remove the hostile oil premium that has impacted pricing for a long time. Although oil remains at $95, Lee described the current market as being in a stasis or a settle-in mode, noting that oil prices have not moved significantly in about two weeks.
Our Methodology
We used screeners to identify NASDAQ stocks that have exhibited strong share price performance over the past 6 months, at least 150%, and have an upside potential of at least 30%. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on May 4.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Performing NASDAQ Stocks According to Wall Street Analysts
10. Commercial Vehicle Group Inc. (NASDAQ:CVGI)
6-Month Performance: 182.78%
Average Upside Potential: 30.33%
Commercial Vehicle Group Inc. (NASDAQ:CVGI) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 1, Commercial Vehicle Group, or simply CVG, announced that Chief Financial Officer Andy Cheung was to resign effective April 15, to join a mid-cap public company. During his tenure, Cheung was credited with leading critical restructuring and refinancing initiatives. In his place, the company promoted Angie O’Leary, the current Corporate Controller and Chief Accounting Officer, to the role of Interim CFO.
O’Leary brings extensive leadership experience to the position, having served as CVG’s Senior Vice President since 2020. Her professional background includes significant roles at Vertiv Holdings Co. and a 13-year career at Deloitte & Touche LLP. A Certified Public Accountant and alumna of The Ohio State University, she will maintain her current responsibilities as Chief Accounting Officer while steering the company’s financial strategy during this transition.
Commercial Vehicle Group Inc. stated it does not currently intend to launch a search for a permanent replacement, opting instead to use O’Leary’s expertise to maintain continuity. Simultaneously, the company reaffirmed its full-year 2026 financial outlook, which was originally issued in March. This move signals stability to investors as the leadership transition takes place under CEO James Ray.
Commercial Vehicle Group Inc. is a global supplier of systems and components for the commercial and EV markets. The company engineers and manufactures solutions to solve complex technical challenges for its international customers.
9. Ultra Clean Holdings Inc. (NASDAQ:UCTT)
6-Month Performance: 168.46%
Average Upside Potential: 37.22%
Ultra Clean Holdings Inc. (NASDAQ:UCTT) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 28, Ultra Clean Holdings announced the retirement of Chief Financial Officer Sheri Savage after 17 years with the company. During her extensive tenure, Savage was a key figure in managing the company’s financial strategy and operational discipline across multiple semiconductor industry cycles. CEO James Xiao highlighted her role as a trusted advisor and credited her with building the financial foundation that has positioned the company for future growth.
In her farewell statement, Savage expressed pride in the company’s global expansion and the strength of its financial position. She noted that it has been an honor to support Ultra Clean Holdings’ customers and work alongside its leadership team for nearly two decades. Her departure marks the end of a significant era for the company’s executive leadership, though she remains confident in the firm’s current trajectory and long-term success.
The Ultra Clean Holdings Inc. Board of Directors has initiated a formal search process to identify her successor, evaluating both internal and external candidates. The company plans to provide further updates as the transition progresses. In the interim, the global finance team remains focused on maintaining the operational excellence established under Savage’s leadership.
Ultra Clean Holdings Inc. is a leading developer and supplier of critical subsystems, components, parts, and ultra-high purity cleaning and analytical services, primarily serving the semiconductor industry.
8. Blue Moon Metals Inc. (NASDAQ:BMM)
6-Month Performance: 184.71%
Average Upside Potential: 52.23%
Blue Moon Metals Inc. (NASDAQ:BMM) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Blue Moon Metals approved a final investment decision to construct the Nussir project in northern Norway. This underground mine and processing facility is expected to begin production in Q3-2027 with a 13-year lifespan. The remaining $184 million in capital costs will be funded through existing cash, a previously announced $140 million finance package, and new equity offerings.
The company also plans to restart production at the Springer Mine and Mill complex in Nevada by Q4-2027. Acquired in early 2026, the site is one of the highest-grade tungsten deposits globally and could become the only major producer in North America. An estimated $50 million is required for the restart, targeting rising global tungsten prices driven by military demand and reduced exports from China.
To support these developments, Blue Moon Metals Inc. entered a C$150 million “bought deal” equity financing agreement. This includes a C$100 million public offering and a C$50 million private placement, both priced at C$10.00 per share and expected to close around May 6. Net proceeds will fund construction at Nussir, development at Springer and Apex, and general corporate activities.
Blue Moon Metals Inc. is a Toronto-based mineral exploration company focused on zinc, gold, silver, and copper deposits in Norway and the US. The firm is currently advancing its flagship, 100%-owned Nussir project in northern Norway.
7. Sensei Biotherapeutics Inc. (NASDAQ:SNSE)
6-Month Performance: 200.36%
Average Upside Potential: 64.20%
Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Sensei Biotherapeutics shifted its focus following the acquisition of Faeth Therapeutics and a concurrent $200 million private placement. The company’s lead program is now PIKTOR, an all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. This new capital, combined with existing cash, is expected to fund clinical operations through major 2026 milestones, including Phase 2 data in endometrial cancer and a Phase 1b trial in breast cancer.
Financial results for the full year 2025 reflect a period of significant cost reduction and restructuring. R&D expenses dropped to $11.0 million from $18.6 million in 2024, while G&A costs fell to $11.3 million. These decreases were largely driven by lower personnel and manufacturing costs, alongside reduced spending on facilities and laboratory supplies.
The company reported a net loss of $21.1 million for 2025, an improvement over the $30.2 million loss recorded the previous year. As of December 31, 2025, Sensei Biotherapeutics Inc. held $21.2 million in cash and marketable securities, down from $41.3 million at the end of 2024. However, the subsequent $200 million financing significantly supports the balance sheet to back the accelerated development of its oncology pipeline.
Sensei Biotherapeutics Inc. is a clinical-stage biotechnology company that treats cancer through multi-node inhibition of critical oncogenic pathways.
6. Velo3D Inc. (NASDAQ:VELO)
6-Month Performance: 161.12%
Average Upside Potential: 66.41%
Velo3D Inc. (NASDAQ:VELO) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Velo3D was awarded a $9.8 million, 5-year contract to support the Defense Logistics Agency’s Joint Additive Manufacturing Acceptability/JAMA Pilot Parts Program. This agreement establishes a streamlined procurement pathway for the US military to acquire metal components produced through additive manufacturing.
The initiative aims to enhance supply chain responsiveness across the Army, Navy, Air Force, Marine Corps, and Space Force. Velo3D Inc. will use its Laser Powder Bed Fusion technology and Rapid Production Solution framework to manufacture complex metal parts. These efforts are specifically targeted at addressing long lead times, domestic supplier shortages, and the obsolescence of components in legacy military systems.
By establishing repeatable technical qualifications, the program seeks to integrate advanced manufacturing directly into operational sustainment. Velo3D’s Sapphire printers, which are assembled in the US, allow for the production of large-scale parts up to one meter in height. The technology includes specialized monitoring to ensure part quality and repeatability across its fleet.
Velo3D Inc. is a metal 3D printing technology company that enables the production of mission-critical parts previously considered impossible to manufacture.
5. Climb Bio Inc. (NASDAQ:CLYM)
6-Month Performance: 379.39%
Average Upside Potential: 69.49%
Climb Bio Inc. (NASDAQ:CLYM) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 28, Climb Bio entered into a securities purchase agreement for a private placement expected to yield approximately $110 million in gross proceeds. The financing involves the sale of 9,481,000 shares of common stock at $9.50 per share, along with pre-funded warrants for an additional 2,106,000 shares.
The offering saw significant participation from a mix of new and existing institutional investors, including RA Capital Management, Adage Capital Partners, and Cormorant Asset Management. Leerink Partners and Piper Sandler served as the lead placement agents for the deal. As part of the agreement, the company committed to filing a registration statement with the SEC within 45 days of closing to allow for the resale of these securities.
While the specific use of proceeds was not detailed in the announcement, the capital injection strengthens Climb Bio Inc.’s (NASDAQ:CLYM) financial position as it advances its therapeutic pipeline. The shares and warrants were issued via a private placement exempt from standard registration requirements under the Securities Act of 1933.
Climb Bio Inc. is a clinical-stage biotech company focused on developing therapies for immune-mediated diseases, with a pipeline centered on monoclonal antibodies targeting B-cell-driven conditions.
4. Damora Therapeutics Inc. (NASDAQ:DMRA)
6-Month Performance: 254.69%
Average Upside Potential: 70.29%
Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30. Jarrett, who will also join the Board of Directors, previously served as COO and CFO at Arcus Biosciences and held executive roles at Uber and Medivation. Her background in oncology drug development and investment banking is expected to accelerate the development of DMR-001, the company’s lead program for mutant calreticulin-driven blood disorders.
In addition to the new CEO, the company has expanded its Board of Directors with the appointments of Dr. Cameron Turtle and Mike Landsittel. Dr. Turtle currently serves as CEO of Spyre Therapeutics, while Landsittel is the former CFO of Blueprint Medicines. Simultaneously, Peter Harwin, a founding partner at Fairmount Funds Management, has been named Chairman of the Board, succeeding departing directors Dr. Carl Goldfischer, Dr. Jayson Dallas, and Amit Munshi.
These leadership changes follow the recent transaction between Damora and Galecto, signaling a strategic shift toward rapid clinical advancement and commercial readiness. The new team will oversee a portfolio aimed at redefining care for myeloproliferative neoplasms. With a reinforced board and executive leadership, the company plans to leverage its strong balance sheet to advance its pipeline assets and deliver value to shareholders.
Damora Therapeutics Inc. is a biotech company focused on redefining care for hematologic disorders. The company is advancing a new generation of biologics targeting mutant calreticulin-driven myeloproliferative neoplasms, such as essential thrombocythemia and myelofibrosis.
3. Immix Biopharma Inc. (NASDAQ:IMMX)
6-Month Performance: 155.18%
Average Upside Potential: 83.05%
Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Immix Biopharma completed enrollment for its NEXICART-2 Phase 2 clinical trial, a key step toward seeking regulatory approval for NXC-201. This therapy targets relapsed/refractory AL Amyloidosis, a condition where the immune system produces toxic proteins that cause organ failure. Topline results from the 40-patient study are expected in Q3 2026, which will be followed by a BLA submission and a planned commercial launch.
NXC-201 is a specialized CAR-T cell therapy designed to eliminate the source of toxic light chains in patients. The treatment has already received several high-priority regulatory labels, including Breakthrough Therapy and Orphan Drug designations from the FDA and EMA. If successful, it would become the first FDA-approved treatment specifically for the relapsed/refractory stage of this disease.
To lead the upcoming regulatory and commercial phases, the company appointed Dr. Richard Graydon as Chief Medical Officer. Dr. Graydon brings extensive experience from Merck and Johnson & Johnson, where he oversaw the approval of major oncology drugs like Keytruda and Darzalex. His expertise is expected to be vital as Immix Biopharma Inc. transitions from a clinical-stage company to a commercial entity following the anticipated BLA filing.
Immix Biopharma Inc. is a clinical-stage biotechnology company focused on treating relapsed/refractory AL Amyloidosis. Its lead candidate, NXC-201, is a BCMA-targeted CAR-T cell therapy designed to eliminate the source of toxic light chains that cause organ failure.
2. Opus Genetics Inc. (NASDAQ:IRD)
6-Month Performance: 165.48%
Average Upside Potential: 83.05%
Opus Genetics Inc. (NASDAQ:IRD) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 6, Opus Genetics secured a financing agreement with Oberland Capital, providing up to $155 million in non-dilutive funding and a $5 million equity investment. This capital infusion, combined with current resources, extends the company’s cash runway into 2029. The funding is designated to support the completion of pivotal studies for OPGx-LCA5 and OPGx-BEST1, initiate pre-launch commercial activities, and advance earlier-stage pipeline programs into clinical testing.
The agreement includes an upfront payment of $35 million in notes and a concurrent purchase of 1.1 million shares of common stock at $4.48 per share. Opus Genetics can access additional tranches of funding over the next 2 years based on clinical milestones, including the potential regulatory approval of its LCA5 program. The notes carry a 7-year maturity with a 6-year interest-only period, providing the financial flexibility to leverage the company’s gene therapy platform while maintaining a focus on inherited retinal diseases/IRDs.
With a strengthened balance sheet, Opus Genetics Inc. plans to transition three additional programs into the clinic over the next year: OPGx-RDH12, OPGx-MERTK, and OPGx-RHO. These programs target rare conditions that cause blindness and affect tens of thousands of patients globally. The company remains on track to report topline results from its Phase 1/2 trial of OPGx-BEST1 in mid-2026, marking a critical step toward restoring vision for patients with limited treatment options.
Opus Genetics Inc. is involved in the research and development of ophthalmic biopharmaceutical products, with a focus on the development and commercialization of therapies for the treatment of several eye disorders.
1. Erasca Inc. (NASDAQ:ERAS)
6-Month Performance: 303.05%
Average Upside Potential: 87.97%
Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS molecular glue targeting solid tumors. In patients with non-small cell lung cancer, the therapy achieved a 62% response rate in late-line settings, rising to 75% for those previously treated with platinum therapies. Results for pancreatic cancer were also significant, showing a 50% response rate at the highest recommended dose of 32 mg daily.
The monotherapy was generally well-tolerated, with most side effects remaining low-grade and no treatment-related discontinuations reported. Pharmacokinetic data showed a steady, dose-dependent increase in exposure, effectively reducing tumor DNA across all tested patients at active dose levels. Early findings also suggest ERAS-0015 can be safely combined with standard treatments like panitumumab for colorectal cancer.
Following these results, the company has narrowed its timeline for disclosing additional expansion and combination cohort data to H1 2027. Monotherapy expansion and combination trials are already underway in the US and China. These milestones support the company’s efforts to position ERAS-0015 as a backbone therapy for a variety of RAS-mutant cancers.
Erasca Inc. is a California-based clinical-stage precision oncology company that provides solutions for patients with RAS/MAPK pathway-driven cancers. The company’s core therapies include ERAS-0015, ERAS-4001, and ERAS-12.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
